Literature DB >> 18692252

Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis.

Cornelia Cudrici1, Takahiro Ito, Ekaterina Zafranskaia, Susanna Weerth, Violeta Rus, Hegang Chen, Florin Niculescu, Katerina Soloviova, Cosmin Tegla, Adrian Gherman, Cedric S Raine, Moon L Shin, Horea Rus.   

Abstract

Complement activation plays a central role in autoimmune demyelination. To explore the possible effects of C5 on post-inflammatory tissue repair, we investigated the transcriptional profile induced by C5 in chronic experimental allergic encephalomyelitis (EAE) using oligonucleotide arrays. We used C5-deficient (C5-d) and C5-sufficient (C5-s) mice to compare the gene expression profile and we found that 390 genes were differentially regulated in C5-s mice as compared to C5-d mice during chronic EAE. Among them, a group of genes belonging to the family of insulin-like growth factor binding proteins (IGFBP) and transforming growth factor (TGF)-beta3 were found most significantly differentially regulated by C5. The dysregulation of these genes suggests that these proteins might be responsible for the gliosis and lack of remyelination seen in C5-d mice with chronic EAE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692252      PMCID: PMC2612730          DOI: 10.1016/j.jneuroim.2008.06.040

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  44 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The membrane attack complex of complement causes severe demyelination associated with acute axonal injury.

Authors:  Richard J Mead; Sim K Singhrao; James W Neal; H Lassmann; B Paul Morgan
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.

Authors:  L Soane; H J Cho; F Niculescu; H Rus; M L Shin
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

Review 4.  The complement system in central nervous system diseases.

Authors:  H Rus; F Niculescu
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis.

Authors:  Rachael Reiman; Craig Gerard; Iain L Campbell; Scott R Barnum
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

6.  Identifying biological themes within lists of genes with EASE.

Authors:  Douglas A Hosack; Glynn Dennis; Brad T Sherman; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

7.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta.

Authors:  José G Abreu; Nan I Ketpura; Bruno Reversade; E M De Robertis
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

9.  Insulin-like growth factor binding proteins-1 and -2 differentially inhibit rat oligodendrocyte precursor cell survival and differentiation in vitro.

Authors:  Nicole M Kühl; Jacques De Keyser; Hans De Vries; Dick Hoekstra
Journal:  J Neurosci Res       Date:  2002-07-15       Impact factor: 4.164

10.  Astrocyte characterization in the multiple sclerosis glial scar.

Authors:  J E Holley; D Gveric; J Newcombe; M L Cuzner; N J Gutowski
Journal:  Neuropathol Appl Neurobiol       Date:  2003-10       Impact factor: 8.090

View more
  11 in total

1.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

2.  Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.

Authors:  Inna Smalley; Vincent Law; Clayton Wyatt; Brittany Evernden; Bin Fang; John M Koomen; Eric A Welsh; Robert J B Macaulay; Peter A Forsyth; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2020-01-10       Impact factor: 12.531

3.  RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis.

Authors:  Violeta Rus; Vinh Nguyen; Alexandru Tatomir; Jason R Lees; Armugam P Mekala; Dallas Boodhoo; Cosmin A Tegla; Irina G Luzina; Paul A Antony; Cornelia D Cudrici; Tudor C Badea; Horea G Rus
Journal:  J Immunol       Date:  2017-03-29       Impact factor: 5.422

4.  C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Monika Rozycka; Katerina Soloviova; Takahiro Ito; Anil K Singh; Aamer Khan; Philippe Azimzadeh; Maria Andrian-Albescu; Anver Khan; Florin Niculescu; Violeta Rus; Susan I V Judge; Horea Rus
Journal:  Exp Mol Pathol       Date:  2011-04-22       Impact factor: 3.362

5.  RGC-32 is a novel regulator of the T-lymphocyte cell cycle.

Authors:  Cosmin A Tegla; Cornelia D Cudrici; Vinh Nguyen; Jacob Danoff; Adam M Kruszewski; Dallas Boodhoo; Armugam P Mekala; Sonia I Vlaicu; Ching Chen; Violeta Rus; Tudor C Badea; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-03-11       Impact factor: 3.362

6.  Epigenetic modifications induced by RGC-32 in colon cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-10-31       Impact factor: 3.362

Review 7.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

8.  RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune encephalomyelitis.

Authors:  Alexandru Tatomir; Cosmin A Tegla; Alvaro Martin; Dallas Boodhoo; Vinh Nguyen; Adam J Sugarman; Armugam Mekala; Freidrich Anselmo; Anamaria Talpos-Caia; Cornelia Cudrici; Tudor C Badea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

9.  Histone Deacetylase SIRT1 Mediates C5b-9-Induced Cell Cycle in Oligodendrocytes.

Authors:  Alexandru Tatomir; Gautam Rao; Dallas Boodhoo; Sonia I Vlaicu; Austin Beltrand; Freidrich Anselmo; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

10.  RGC-32 Regulates Generation of Reactive Astrocytes in Experimental Autoimmune Encephalomyelitis.

Authors:  Alexandru Tatomir; Austin Beltrand; Vinh Nguyen; Dallas Boodhoo; Armugam Mekala; Cornelia Cudrici; Tudor C Badea; Dafin F Muresanu; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.